









Markets
/
Stocks
/
nasdaq-ivvd
/

Invivyd Inc

IVVD

1.220USD

-0.030-2.40%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

146.57MMarket Cap

LossP/E TTM



Invivyd Inc

1.220

-0.030-2.40%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

41 / 175

Overall Ranking

138 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

3.000

Target Price

+140.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Growing

The company is in a growing phase, with the latest annual income totaling USD 25.38M.

Undervalued

The company’s latest PE is -1.33, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 126.73M shares, increasing 2.48% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 16.73M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.87.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.67, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 11.79M, representing a year-over-year increase of 420.58%, while its net profit experienced a year-over-year increase of 68.97%.

Score

Industry at a Glance

Previous score

7.67

Change



Financials

6.68

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.83

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.21

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -1.36, which is -50.21% below the recent high of -0.68 and 20.19% above the recent low of -1.09.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 41/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Invivyd Inc is 3.00, with a high of 5.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

3.000

Target Price

+140.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Invivyd Inc

IVVD

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.91, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 1.64 and the support level at 0.67, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.91

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.004

Buy

RSI(14)

58.312

Neutral

STOCH(KDJ)(9,3,3)

47.073

Sell

ATR(14)

0.156

High Vlolatility

CCI(14)

21.146

Neutral

Williams %R

45.890

Neutral

TRIX(12,20)

2.485

Buy

StochRSI(14)

30.199

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.232

Sell

MA10

1.249

Sell

MA20

1.082

Buy

MA50

0.872

Buy

MA100

0.821

Buy

MA200

0.788

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 105.64%, representing a quarter-over-quarter decrease of 8.96%. The largest institutional shareholder is Steven Cohen, holding a total of 16.73M shares, representing 7.99% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Adimab, L.L.C.

21.69M

-18.74%

Mithril Capital Management LLC

11.24M

Royan (Ajay G.)

11.21M

Maverick Capital, Ltd.

Star Investors

10.96M

-6.86%

M28 Capital Management LP

9.25M

Deep Track Capital LP

9.72M

-9.05%

Polaris Venture Partners

7.93M

-7.01%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.04, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.